top of page

Search Results

搜尋此網站

以空白搜尋找到 547 個結果

  • FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer

    The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit. Summit Therapeutics announced on 15 November 2026 that the US Food and Drug Administration had declined to approve ivonescimab in combination with platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior EGFR-targeted treatment, issuing a Complete Response Letter in response to the company's biologics licence application. The decision followed review of the HARMONi clinical trial, which showed improvement in progression-free survival without establishing a statistically significant overall-survival benefit in the submitted analysis; ivonescimab is an investigational PD-1 × VEGF bispecific antibody developed by Akeso and licensed to Summit, and the regulatory setback does not represent a clinical hold or permanent discontinuation of the programme. Field Content Article Type Approvals Regulatory Event FDA Complete Response Letter Regulatory Outcome Approval declined Company Summit Therapeutics Originating Developer Akeso Investigational Medicine Ivonescimab Drug Modality Bispecific antibody Molecular Targets PD-1 and VEGF Regulatory Authority US Food and Drug Administration Announcement Date 15 November 2026 Regulatory Submission Biologics licence application Proposed Treatment Ivonescimab plus platinum-containing chemotherapy Therapeutic Area Oncology Cancer Type Non-small cell lung cancer Molecular Subtype EGFR-mutated Proposed Patient Population Patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior EGFR-targeted therapy Treatment Setting After prior EGFR-targeted treatment Supporting Clinical Trial HARMONi Progression-Free Survival Finding Benefit demonstrated Overall Survival Finding Statistically significant benefit not established in the submitted analysis Regulatory Concern Overall-survival evidence did not establish the required benefit US Marketing Approval Granted No Clinical Hold Imposed Not reported Programme Permanently Terminated Not reported Commercial Launch Authorised No What Happened The FDA issued a Complete Response Letter declining Summit's application for ivonescimab in EGFR-mutated lung cancer. Why It Matters The decision creates a significant regulatory obstacle for a high-profile bispecific antibody programme in lung cancer. Clinical Significance The regulatory outcome highlights the importance of overall-survival evidence alongside progression-free survival in oncology development. Strategic Significance The setback affects Summit's US development and commercialisation plans for ivonescimab. Regulatory Clarification A Complete Response Letter is not an approval and does not necessarily end future development or resubmission. Key Takeaway Ivonescimab has not received FDA approval for the submitted EGFR-mutated lung cancer indication. What to Watch Summit's response to the FDA, additional survival analyses, potential regulatory discussions and any future resubmission. Primary Source Summit Therapeutics Primary Source URL https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application-2026.pdf Submitted Source Reuters Submitted Source URL https://www.reuters.com/legal/litigation/us-fda-declines-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-2026-11-15/ Relevant Date 15 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer

    Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028. Biocon announced on 16 November 2026 that the US Food and Drug Administration had approved Pebrilzo (pertuzumab-qcay), a biosimilar to Genentech's Perjeta, for HER2-positive breast cancer, marking the company's fifth oncology biosimilar approval in the United States. Although the approval establishes a new regulatory milestone and a potential additional biosimilar treatment option, Biocon's global patent settlement with Genentech provides for the earliest licensed US commercial launch in the third quarter of 2028, meaning the decision does not constitute immediate market availability or evidence that Pebrilzo is clinically superior to the reference medicine. Field Content Article Type Approvals Company Biocon Product Brand Name Pebrilzo Active Ingredient Pertuzumab-qcay Product Classification Biosimilar Reference Product Perjeta Reference Product Company Genentech Regulatory Authority US Food and Drug Administration Announcement Date 16 November 2026 Regulatory Decision FDA biosimilar approval Regulatory Market United States Therapeutic Area Oncology Cancer Type Breast cancer Molecular Subtype HER2-positive Therapeutic Target HER2 Biocon US Oncology Biosimilar Portfolio Position Fifth oncology biosimilar Approval Status Approved US Commercial Launch Status Not yet launched Earliest Licensed US Launch Third quarter of 2028 Launch Timing Basis Global patent settlement with Genentech Patent Settlement Counterparty Genentech Reference Medicine Comparison Biosimilar to Perjeta Clinical Superiority Established No Immediate US Commercial Availability No What Happened The FDA approved Biocon's Pebrilzo as a biosimilar to pertuzumab reference medicine Perjeta. Why It Matters The approval expands the potential future range of biosimilar treatment options for HER2-positive breast cancer. Regulatory Significance Adds another FDA-approved oncology biosimilar to Biocon's portfolio. Commercial Significance Establishes regulatory readiness ahead of a planned US market entry permitted from the third quarter of 2028. Access Implications Future commercial entry may introduce additional competition in HER2-targeted oncology treatment. Launch Clarification FDA approval and commercial launch are separate milestones. Patent Clarification The reported patent settlement sets the earliest licensed US launch timing. Key Takeaway Pebrilzo has received FDA approval, but its earliest licensed US launch is scheduled for the third quarter of 2028. What to Watch Commercial launch preparations, patent settlement implementation, market access, pricing and adoption after launch. Primary Source Biocon Primary Source URL https://www.biocon.com/biocon-gets-u-s-fda-approval-for-pebrilzo-pertuzumab-qcay-injection-a-biosimilar-to-perjeta-expanding-its-oncology-portfolio/ Submitted Source Business Standard Submitted Source URL https://www.business-standard.com/companies/news/biocon-secures-us-fda-approval-for-pebrilzo-its-fifth-cancer-biosimilar-126111600687_1.html Relevant Date 16 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe

    The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation. Innovent announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on 12 November 2026 recommending Zybrivo (sintilimab) in combination with chemotherapy for first-line treatment of eligible adults with non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, regardless of PD-L1 expression. The recommendation is supported by clinical evidence showing improved progression-free survival compared with chemotherapy alone and represents an important European regulatory milestone for the PD-1-targeting immunotherapy, but the European Commission must still issue its final marketing authorisation decision before the recommendation becomes an EU approval. Field Content Article Type Approvals Company Innovent Product Brand Name Zybrivo Active Ingredient Sintilimab Drug Classification Immune checkpoint inhibitor Molecular Target PD-1 Regulatory Authority European Medicines Agency Regulatory Committee Committee for Medicinal Products for Human Use Regulatory Committee Abbreviation CHMP Opinion Date 12 November 2026 Regulatory Outcome Positive CHMP opinion Regulatory Recommendation Marketing authorisation recommended Final European Commission Approval Not yet granted according to supplied summary Regulatory Market European Union Therapeutic Area Oncology Cancer Type Non-small cell lung cancer Histological Subtype Non-squamous Treatment Line First line Proposed Treatment Regimen Sintilimab in combination with chemotherapy Proposed Patient Population Eligible adults with non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations EGFR Status Requirement No EGFR genomic aberrations ALK Status Requirement No ALK genomic aberrations PD-L1 Eligibility Irrespective of PD-L1 expression Supporting Clinical Evidence Clinical trial evidence of improved progression-free survival Progression-Free Survival Finding Improvement versus chemotherapy alone Overall Survival Results Not specified in supplied summary Commercial Launch Status Not yet authorised for launch on the basis of this CHMP opinion What Happened The CHMP recommended European marketing authorisation for Zybrivo in a specified first-line lung cancer setting. Why It Matters The recommendation moves another immunotherapy option closer to potential availability for eligible European lung cancer patients. Clinical Significance Supporting evidence demonstrated improved progression-free survival when sintilimab was combined with chemotherapy. Regulatory Significance Represents a positive scientific opinion preceding a potential European Commission marketing authorisation. Regulatory Clarification A positive CHMP opinion is not a final European Commission approval. Key Takeaway Zybrivo has received a positive CHMP recommendation for first-line non-squamous lung cancer, with the final EU authorisation decision still pending. What to Watch European Commission decision, final authorised product information, reimbursement assessments and European commercialisation plans. Primary Source European Medicines Agency Primary Source URL https://www.ema.europa.eu/en/medicines/human/EPAR/zybrivo Submitted Source Innovent announcement Submitted Source URL https://www.prnewswire.com/news-releases/innovent-announces-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-first-line-treatment-of-non-squamous-non-small-cell-lung-cancer-302939658.html Relevant Date 12 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion

    OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties. OBI Pharma announced on 13 November 2026 that it had signed a collaboration and licensing agreement granting Novartis exclusive worldwide rights to selected applications of its antibody-drug conjugate platform technologies, supporting the development of next-generation ADC therapies and novel payload approaches. Under the agreement, OBI will receive $30 million upfront and may earn development, regulatory and commercial milestone payments that bring the total potential agreement value above $2 billion, together with tiered royalties; the majority of the headline value is contingent on future achievements, and the transaction is a technology licensing partnership rather than an acquisition of OBI Pharma or an approved drug. Field Content Article Type Deals Licensor OBI Pharma Licensee Novartis Deal Type Technology platform collaboration and licensing agreement Announcement Date 13 November 2026 Agreement Status Signed Licensed Technology Antibody-drug conjugate platform technologies Technology Abbreviation ADC Development Focus Next-generation antibody-drug conjugates Additional Technology Focus Novel ADC payload development Licence Scope Selected applications of OBI Pharma's ADC platform technologies Licence Exclusivity Exclusive Territorial Rights Worldwide Upfront Payment $30 million Total Potential Deal Value More than $2 billion Additional Consideration Development, regulatory and commercial milestone payments Royalty Structure Tiered royalties Royalty Rates Not disclosed in supplied summary Milestone Payment Status Contingent on future achievements Guaranteed Total Deal Value Not more than the disclosed upfront payment based on supplied information Therapeutic Modality Antibody-drug conjugates Therapeutic Area Oncology drug development Asset Acquisition No Company Acquisition No Approved Medicine Included Not reported What Happened OBI Pharma licensed selected ADC platform technologies to Novartis under an exclusive worldwide collaboration. Why It Matters The partnership provides a major pharmaceutical company with access to emerging ADC technology while potentially generating substantial future revenue for the technology developer. Strategic Significance Supports Novartis' exploration of next-generation targeted oncology therapies and validates commercial interest in OBI's platform. Financial Significance The agreement includes $30 million upfront and more than $2 billion in potential total value. Financial Clarification Most of the headline agreement value depends on future development, regulatory and commercial milestones. Transaction Clarification This is a licensing and collaboration agreement, not an acquisition. Key Takeaway Novartis has secured exclusive worldwide rights to selected OBI Pharma ADC technologies under a deal potentially worth more than $2 billion. What to Watch Selection of development programmes, preclinical and clinical progress, milestone achievements and future ADC pipeline disclosures. Primary Source OBI Pharma Primary Source URL https://www.obipharma.com/news/signs-collaboration-and-license-agreement-with-novartis/ Submitted Source The Globe and Mail Submitted Source URL https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8842040/obi-pharma-signs-adc-platform-collaboration-and-license-agreement-with-novartis/ Relevant Date 13 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Sandoz launches Enzeevu aflibercept biosimilar in US with new private-label distribution agreement

    Sandoz has launched its interchangeable aflibercept biosimilar Enzeevu in the United States and announced a multi-year private-label distribution arrangement, expanding commercial competition in treatments for retinal vascular diseases. Sandoz announced on 16 November 2026 that it had commercially launched Enzeevu (aflibercept-abzv), an interchangeable biosimilar to Eylea, in the United States as a 2 mg pre-filled syringe for approved ophthalmic indications including neovascular age-related macular degeneration and diabetic macular oedema. The company also disclosed a multi-year private-label distribution agreement establishing an additional US commercial channel from mid-2027, with committed volumes expected from the second half of that year; Enzeevu originally received FDA approval in August 2024, so the November announcement concerns market launch and distribution rather than a newly granted regulatory approval. Field Content Article Type Industry Updates Company Sandoz Product Brand Name Enzeevu Active Ingredient Aflibercept-abzv Product Classification Interchangeable biosimilar Reference Product Eylea Announcement Date 16 November 2026 Event Type US commercial product launch and distribution agreement Commercial Launch Market United States Commercial Launch Status Launched Original FDA Approval Date August 2024 New FDA Approval Announced No Therapeutic Area Ophthalmology Disease Category Retinal vascular diseases Indication One Neovascular age-related macular degeneration Indication One Abbreviation nAMD Indication Two Diabetic macular oedema Product Presentation 2 mg pre-filled syringe Biosimilar Regulatory Status FDA-approved interchangeable biosimilar Distribution Agreement Type Multi-year private-label agreement Additional Commercial Channel US private-label distribution Private-Label Channel Start Mid-2027 Expected Committed Volumes From the second half of 2027 Distribution Partner Not specified in supplied summary Agreement Financial Terms Not disclosed in supplied summary Commercial Strategy Expand access and distribution of an interchangeable ophthalmic biosimilar What Happened Sandoz launched Enzeevu in the US and announced an additional private-label commercial distribution arrangement. Why It Matters The launch adds a commercial biosimilar alternative in the US market for widely used retinal disease treatments. Commercial Significance Establishes immediate US market presence with a further distribution channel planned for 2027. Access Significance Additional biosimilar competition may broaden treatment and purchasing options for retinal disease care. Regulatory Clarification The FDA approved Enzeevu in August 2024; November 2026 marks commercial launch rather than a new approval. Distribution Clarification The private-label channel is expected to begin in mid-2027, with committed volumes from the second half of that year. Key Takeaway Enzeevu is commercially available in the US, with Sandoz planning an additional private-label distribution channel in 2027. What to Watch US market uptake, reimbursement, pricing competition, private-label rollout and committed distribution volumes. Primary Source Sandoz Primary Source URL https://www.sandoz.com/sandoz-launches-enzeevu-us-and-announces-key-private-label-agreement-expanding-treatment-choice/ Submitted Source EQS News Submitted Source URL https://www.eqs-news.com/news/ad-hoc/sandoz-launches-enzeevu-in-the-us-and-announces-key-private-label-agreement-expanding-treatment-choice-for-patients-with-retinal-diseases/c8143ba5-e941-4ff0-b594-c7355a3372fa_en Relevant Date 16 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Lupin and Sandoz launch Ranluspec ranibizumab biosimilar across Europe following EC approval

    Lupin and commercial partner Sandoz have begun launching Ranluspec, a ranibizumab biosimilar, across European markets excluding Germany, expanding commercial competition in treatments for retinal vascular diseases. Lupin announced on 12 November 2026 that Sandoz had launched Ranluspec, Lupin's ranibizumab biosimilar, in European markets excluding Germany following an existing European Commission marketing authorisation covering vial and pre-filled syringe presentations for approved ophthalmic indications. Ranluspec targets vascular endothelial growth factor A and is intended for retinal conditions including neovascular age-related macular degeneration, diabetic macular oedema and macular oedema associated with retinal vein occlusion, with the announcement marking commercial market entry rather than a newly granted European Commission approval. Field Content Article Type Industry Updates Developer Lupin Commercial Partner Sandoz Product Ranluspec Active Ingredient Ranibizumab Product Classification Biosimilar Reference Medicine Class Anti-VEGF ophthalmic therapy Molecular Target Vascular endothelial growth factor A Target Abbreviation VEGF-A Announcement Date 12 November 2026 Event Type European commercial biosimilar launch Launch Status Announced Geographic Scope European markets excluding Germany Explicitly Excluded Market Germany Regulatory Basis Existing European Commission marketing authorisation New European Commission Approval No Available Presentation One Vial Available Presentation Two Pre-filled syringe Therapeutic Area Ophthalmology Indication One Neovascular age-related macular degeneration Indication One Abbreviation nAMD Indication Two Diabetic macular oedema Indication Three Macular oedema associated with retinal vein occlusion Treatment Mechanism VEGF-A inhibition Commercialisation Responsibilities Sandoz commercial launch Developer Responsibilities Lupin developed the biosimilar Product Pricing Not disclosed in supplied summary Market Share Expectations Not disclosed What Happened Lupin announced the European commercial launch of its ranibizumab biosimilar through Sandoz. Why It Matters The launch adds biosimilar competition in retinal disease treatment markets and may expand purchasing and treatment options. Commercial Significance Moves an already authorised biosimilar into European commercial distribution. Regulatory Clarification The event is a market launch following existing approval rather than a new European Commission marketing authorisation. Geographic Clarification Germany is explicitly excluded from the announced European launch footprint. Key Takeaway Sandoz has launched Lupin's Ranluspec across European markets other than Germany. What to Watch Country-level availability, reimbursement, pricing, uptake, competition and potential future expansion into additional markets. Primary Source Lupin Primary Source URL https://www.lupin.com/media/press-releases/lupin-announces-european-launch-of-biosimilar-ranibizumab Relevant Date 12 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • PharmaLogic agrees to acquire Lantheus radiopharmaceutical CDMO business and New Jersey manufacturing facility

    PharmaLogic has signed a definitive agreement to acquire Lantheus' radiopharmaceutical CDMO operations and Springfield manufacturing facility, expanding specialist production capabilities for therapeutic radiopharmaceuticals. PharmaLogic announced on 9 November 2026 that it had entered into a definitive agreement to acquire Lantheus' contract development and manufacturing operations together with its Springfield, New Jersey radiopharmaceutical manufacturing facility, with financial consideration undisclosed and completion still pending. The planned acquisition would expand PharmaLogic's therapeutic radiopharmaceutical manufacturing capacity and integrate the acquired operations into its Agilera business to support a transatlantic CDMO platform for radioligand therapies, while remaining separate from Curium's pending acquisition of Lantheus and involving no newly announced regulatory approval. Field Content Article Type Deals Acquirer PharmaLogic Seller Lantheus Deal Type Definitive asset and manufacturing business acquisition agreement Announcement Date 9 November 2026 Transaction Status Agreed; completion pending Acquired Business Radiopharmaceutical contract development and manufacturing operations Acquired Facility Springfield radiopharmaceutical manufacturing facility Facility Location Springfield, New Jersey, United States Industry Segment Radiopharmaceutical manufacturing Manufacturing Service Category Contract development and manufacturing organisation Service Category Abbreviation CDMO Therapeutic Focus Therapeutic radiopharmaceuticals Related Treatment Modality Radioligand therapy Receiving Business Agilera Planned Integration Integration into PharmaLogic's Agilera business Geographic Platform Objective Transatlantic CDMO operations Strategic Objective Expand specialist radiopharmaceutical manufacturing capacity Purchase Price Not disclosed Upfront Consideration Not disclosed Contingent Consideration Not disclosed Closing Date Not specified in supplied summary Regulatory Approval Announced No Related Corporate Transaction Curium's pending acquisition of Lantheus Relationship to Curium Transaction Separate transaction What Happened PharmaLogic signed a definitive agreement to acquire Lantheus' radiopharmaceutical CDMO operations and New Jersey manufacturing facility. Why It Matters The transaction could increase specialist manufacturing capacity needed to support the growing radiopharmaceutical and radioligand therapy sector. Strategic Significance Strengthens PharmaLogic's manufacturing platform and broadens Agilera's potential service capabilities. Industry Significance Illustrates consolidation of specialised pharmaceutical manufacturing infrastructure supporting nuclear medicine therapies. Transaction Clarification The acquisition is agreed but has not been reported as completed. Financial Clarification The purchase consideration has not been disclosed and should not be inferred from other Lantheus transactions. Key Takeaway PharmaLogic plans to add Lantheus' CDMO operations and Springfield facility to its radiopharmaceutical manufacturing platform. What to Watch Transaction completion, facility integration, manufacturing capacity expansion and future radioligand therapy CDMO contracts. Primary Source PharmaLogic announcement Primary Source URL https://www.prnewswire.com/news-releases/pharmalogic-to-acquire-lantheus-cdmo-business-and-springfield-new-jersey-manufacturing-facility-302933626.html Submitted Source Fierce Pharma Submitted Source URL https://www.fiercepharma.com/pharma/radiopharma-player-pharmalogic-snaps-lantheus-cdmo-business-plant-curium-acquisition Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • European Commission expands Oncopeptides' Pepaxti authorisation to third-line multiple myeloma

    The European Commission has approved an expansion of Oncopeptides' Pepaxti label into third-line multiple myeloma treatment, broadening eligibility after two prior lines of therapy and removing the previous triple-class refractory requirement. Oncopeptides announced on 9 November 2026 that the European Commission had approved a Type II variation extending the authorised use of Pepaxti (melphalan flufenamide) with dexamethasone to eligible adults with multiple myeloma after at least two prior treatment lines whose disease is refractory to lenalidomide and their last line of treatment, subject to the full approved product information. The decision shifts Pepaxti's European treatment positioning from fourth-line to third-line use and removes the earlier triple-class refractory requirement, potentially expanding the eligible patient population; Oncopeptides estimates the addressable European market could approximately double, although that projection is not evidence of actual patient uptake or commercial sales. Field Content Article Type Approvals Company Oncopeptides Product Pepaxti Active Ingredient Melphalan flufenamide Combination Medicine Dexamethasone Regulatory Authority European Commission Announcement Date 9 November 2026 Regulatory Decision Marketing authorisation label expansion Variation Type Type II variation Geographic Scope European Union Therapeutic Area Haematology and oncology Disease Multiple myeloma Patient Population Eligible adults with multiple myeloma meeting the revised authorised treatment criteria Minimum Prior Treatment Lines At least two Refractory Disease Requirement One Refractory to lenalidomide Refractory Disease Requirement Two Refractory to the last line of therapy New Treatment Position Third-line treatment Previous Treatment Position Fourth-line treatment Previous Triple-Class Refractory Requirement Removed under the expanded authorisation Treatment Regimen Pepaxti in combination with dexamethasone Previous Regulatory Step September 2026 CHMP opinion Final Regulatory Step European Commission approval First European Authorisation No New CHMP Opinion No; final EC decision follows the earlier opinion Estimated Change in Addressable Patient Population Potentially approximately double Market Expansion Estimate Source Oncopeptides Market Expansion Estimate Status Company projection rather than observed treatment uptake Commercial Sales Impact Not yet established What Happened The European Commission approved broader Pepaxti eligibility for eligible patients with relapsed or refractory multiple myeloma. Why It Matters The expanded label potentially makes the treatment available earlier in the multiple myeloma treatment pathway. Clinical Significance The authorisation reduces the number of required previous treatment lines and removes the former triple-class refractory restriction. Commercial Significance Oncopeptides anticipates a substantially larger eligible European patient population. Regulatory Clarification This is a final European Commission label expansion rather than a new product authorisation or CHMP recommendation. Key Takeaway Pepaxti can be used in an expanded third-line European multiple myeloma population subject to the full authorised label. What to Watch Country-level reimbursement, clinical adoption, patient access, European sales and real-world outcomes. Primary Source Oncopeptides Primary Source URL https://oncopeptides.com/press-releases/european-commission-approves-label-expansion-of-pepaxti-to-third-line-treatment/ Submitted Source BioStock Submitted Source URL https://biostock.se/en/2026/11/oncopeptides-om-eu-godkannandet-som-flyttar-pepaxti-till-tredje-linjen/ Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • UK MHRA approves Incyte's Zynyz for advanced anal cancer as NICE backs NHS access

    The UK MHRA has authorised Incyte's Zynyz with carboplatin and paclitaxel for advanced anal cancer, accompanied by a positive NICE access recommendation and Phase III evidence of improved median overall survival. The UK Medicines and Healthcare products Regulatory Agency announced on 11 November 2026 that it had authorised retifanlimab (Zynyz) in combination with carboplatin and paclitaxel for adults with unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal, establishing a new UK treatment indication for Incyte's immunotherapy. NICE also supported access for eligible patients in England and Wales, with initial Cancer Drugs Fund availability and subsequent routine commissioning described in contemporary reporting, while the pivotal POD1UM-303 trial reported median overall survival of 32.8 months with the retifanlimab combination compared with 22.2 months for chemotherapy plus placebo; the UK decision is distinct from earlier approvals in other jurisdictions. Field Content Article Type Approvals Company Incyte Product Brand Name Zynyz Active Ingredient Retifanlimab Regulatory Authority UK Medicines and Healthcare products Regulatory Agency Regulatory Authority Abbreviation MHRA Announcement Date 11 November 2026 Regulatory Decision UK marketing authorisation for an advanced anal cancer indication Approved Regimen Retifanlimab plus carboplatin and paclitaxel Immunotherapy Component Retifanlimab Chemotherapy Component One Carboplatin Chemotherapy Component Two Paclitaxel Therapeutic Area Oncology Cancer Type Squamous cell carcinoma of the anal canal Approved Population Adults with unresectable locally recurrent or metastatic disease Disease Stage Unresectable locally recurrent or metastatic Treatment Setting Advanced anal cancer Health Technology Assessment Body National Institute for Health and Care Excellence HTA Body Abbreviation NICE NICE Outcome Positive NHS access recommendation NICE Geographic Scope England and Wales Initial Access Route Cancer Drugs Fund according to contemporary reporting Routine Commissioning Timeline Expected within 90 days according to contemporary reporting Supporting Clinical Trial POD1UM-303 Clinical Trial Phase Phase III Key Efficacy Endpoint Overall survival Median Overall Survival With Retifanlimab Combination 32.8 months Median Overall Survival With Chemotherapy and Placebo 22.2 months Reported Median Overall Survival Difference 10.6 months Prior International Regulatory Context Earlier US and EU approvals Separate UK Indication Merkel cell carcinoma What Happened The MHRA authorised a new advanced anal cancer indication for Zynyz with chemotherapy and NICE supported patient access. Why It Matters The decision creates an additional immunotherapy-based treatment option for patients with difficult-to-treat advanced anal cancer. Clinical Significance The pivotal trial reported longer median overall survival with the retifanlimab combination than with chemotherapy and placebo. Regulatory Significance Represents a UK indication approval distinct from previous international authorisations. Access Significance The NICE recommendation supports a pathway toward NHS availability for eligible patients. Key Takeaway Zynyz plus carboplatin and paclitaxel has gained UK approval for advanced anal cancer alongside a positive NICE access recommendation. What to Watch NHS implementation, patient access, real-world treatment outcomes and longer-term survival and safety evidence. Primary Source UK Medicines and Healthcare products Regulatory Agency Primary Source URL https://www.gov.uk/government/news/mhra-approves-retifanlimab-zynyz-for-the-treatment-of-advanced-anal-cancer Submitted Source pharmaphorum Submitted Source URL https://pharmaphorum.com/news/nhs-use-incytes-anal-cancer-drug-zynyz-backed-nice Relevant Date 11 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Pfizer and Blackstone agree up to $1.5 billion in development funding for monthly GLP-1 obesity candidate berobenatide

    Pfizer and Blackstone Life Sciences have agreed a development co-funding arrangement of up to $1.5 billion for investigational once-monthly GLP-1 therapy berobenatide, sharing clinical development risk while Pfizer retains control of the programme. Pfizer and Blackstone Life Sciences announced a strategic funding agreement on 11 November 2026 under which Blackstone-managed funds will provide up to $1.5 billion through 2028 toward the clinical development of berobenatide, an investigational once-monthly injectable GLP-1 receptor agonist being studied for chronic weight management and obesity-related conditions. Under the arrangement, Blackstone may receive payments linked to US regulatory approval of monthly injectable berobenatide monotherapy and specified commercial sales milestones, while Pfizer retains the programme and its development responsibilities; the $1.5 billion represents a maximum development funding commitment rather than an acquisition price, guaranteed upfront consideration or regulatory approval. Field Content Article Type Deals Pharmaceutical Company Pfizer Funding Partner Blackstone Life Sciences Funding Source Blackstone-managed funds Deal Type Strategic clinical development co-funding agreement Announcement Date 11 November 2026 Agreement Status Announced Funded Programme Berobenatide Drug Development Status Investigational Drug Class GLP-1 receptor agonist Drug Modality Injectable medicine Proposed Dosing Frequency Once monthly Therapeutic Area Obesity and metabolic disease Primary Development Focus Chronic weight management Additional Development Focus Obesity-related conditions Maximum Funding Commitment Up to $1.5 billion Funding Period Through 2028 Funding Purpose Clinical development costs Funding Structure Development co-funding with contingent return payments Funding Provider Consideration Potential payments linked to regulatory and commercial milestones Regulatory Payment Trigger US regulatory approval of monthly injectable berobenatide monotherapy Commercial Payment Triggers Specified sales milestones Commercial Milestone Amounts Not disclosed in supplied summary Programme Ownership Retained by Pfizer Development Responsibilities Retained by Pfizer Acquisition Involved No Guaranteed Upfront Acquisition Payment Not applicable Regulatory Approval Granted No What Happened Pfizer and Blackstone Life Sciences agreed to share funding and financial exposure associated with berobenatide clinical development. Why It Matters The arrangement provides substantial external financing for an obesity programme while allowing Pfizer to retain ownership and development control. Strategic Significance Illustrates a risk-sharing financing model for capital-intensive late-stage pharmaceutical development. Financial Clarification The up to $1.5 billion figure is a funding commitment through 2028 rather than a purchase price or guaranteed cash payment to Pfizer. Regulatory Clarification Berobenatide remains investigational and any future regulatory approval is contingent. Key Takeaway Blackstone-managed funds may contribute up to $1.5 billion toward Pfizer's monthly GLP-1 development programme in return for contingent future payments. What to Watch Clinical development milestones, efficacy and safety results, US regulatory progress, funding deployment and potential commercial milestone obligations. Primary Source Blackstone Primary Source URL https://www.blackstone.com/news/press/pfizer-and-blackstone-life-sciences-announce-strategic-funding-agreement-for-obesity-program/ Submitted Source pharmaphorum Submitted Source URL https://pharmaphorum.com/news/blackstone-buys-pfizers-glp-1-drug-development Relevant Date 11 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA requires new NAION vision-loss risk warnings across GLP-1 receptor agonist medicines

    The FDA has ordered class-wide labelling changes for GLP-1 receptor agonists following evidence of a potential association with rare but potentially permanent vision loss caused by non-arteritic anterior ischaemic optic neuropathy. The US Food and Drug Administration issued a drug safety communication on 9 November 2026 requiring manufacturers of GLP-1 receptor agonist medicines to add warnings about the potential increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION), a rare condition that can cause sudden and permanent vision loss, to the Warnings and Precautions section of product labelling. The agency's analysis of 126 randomised clinical trials involving 134253 participants identified 6.4 probable NAION cases per 100000 person-years among GLP-1 receptor agonist recipients compared with 3.8 among comparators, supporting a new precautionary labelling requirement without establishing causation for every medicine or constituting a product withdrawal, contraindication or new approval. Field Content Article Type Industry Updates Regulatory Authority US Food and Drug Administration Regulatory Action Class-wide drug safety labelling changes Communication Date 9 November 2026 Affected Drug Class GLP-1 receptor agonists Drug Class Full Name Glucagon-like peptide-1 receptor agonists Geographic Scope United States Required Label Section Warnings and Precautions Identified Safety Concern Potential increased risk of non-arteritic anterior ischaemic optic neuropathy Condition Abbreviation NAION Affected Organ System Eye and optic nerve Potential Clinical Consequence Sudden and potentially permanent vision loss Safety Signal Classification Potential risk identified through FDA evidence review Evidence Source FDA analysis of randomised clinical trials Number of Trials Analysed 126 Total Participants 134253 GLP-1 Group NAION Incidence 6.4 probable cases per 100000 person-years Comparator Group NAION Incidence 3.8 probable cases per 100000 person-years Absolute Incidence Difference 2.6 probable cases per 100000 person-years Event Frequency Rare Causation Established for Every Medicine No Manufacturer Requirement Update product labelling with the specified safety warning Regulatory Status of Affected Medicines Existing approvals remain in place Drug Withdrawal No New Contraindication Not described in supplied summary New Drug Approval No What Happened The FDA required GLP-1 receptor agonist manufacturers to add NAION risk information to product warnings. Why It Matters The labelling change affects a widely used therapeutic class and provides clinicians and patients with additional information about a potentially serious ocular safety risk. Clinical Significance NAION is uncommon but can cause irreversible visual impairment, making recognition of potential symptoms important. Regulatory Significance The action introduces a class-wide safety warning based on the FDA's assessment of available clinical trial evidence. Evidence Interpretation The reported incidence difference supports a potential safety signal but does not prove causality for every individual GLP-1 medicine. Key Takeaway The FDA has introduced new NAION warnings across GLP-1 receptor agonist labelling without withdrawing the medicines. What to Watch Implementation of revised labels, additional ophthalmic safety evidence, pharmacovigilance findings and clinical prescribing guidance. Primary Source US Food and Drug Administration Primary Source URL https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential Submitted Source Review of Optometry Submitted Source URL https://www.reviewofoptometry.com/news/article/fda-adds-naion-risk-warning-to-glp1-labeling Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Teva targets $6–7 billion in innovative medicines revenue by 2030 as it outlines expanded R&D strategy

    Teva has unveiled an expanded innovative-medicines strategy targeting $6–7 billion in annual revenue by 2030, supported by seven late-stage pipeline assets, potential annual launches and a broader R&D investment programme. Teva Pharmaceutical Industries outlined its updated research and development strategy on 11 November 2026, setting a target of $6–7 billion in annual innovative medicines revenue by 2030 and describing a potential cadence of one new innovative medicine launch each year over the following five years, supported by seven late-stage pipeline assets. The company also highlighted more than $10 billion in combined potential peak sales across its pipeline, positive primary-endpoint results from a Phase IIa anti-IL-15 study in coeliac disease, innovative-medicines gross margin ambitions above 75% and a free cash flow target exceeding $3.5 billion by 2030, with all financial projections and future launches remaining forward-looking rather than achieved outcomes. Field Content Article Type Industry Updates Company Teva Pharmaceutical Industries Event Research and Development Day strategy update Announcement Date 11 November 2026 Industry Segment Innovative pharmaceutical medicines Strategic Focus Expansion of innovative medicines research, development and commercialisation Innovative Medicines Revenue Target $6–7 billion annually by 2030 Revenue Target Year 2030 Revenue Target Status Forward-looking company objective Potential Launch Cadence Approximately one new innovative medicine annually over the next five years Launch Forecast Status Potential; not guaranteed Late-Stage Pipeline Assets Seven Combined Potential Peak Sales More than $10 billion Peak Sales Estimate Status Company estimate; non-risk-adjusted and not achieved sales Highlighted Research Programme Anti-IL-15 programme for coeliac disease Highlighted Clinical Study Phase IIa coeliac disease study Reported Clinical Outcome Primary endpoint met Study Efficacy Details Not specified in supplied summary Innovative Medicines Gross Margin Ambition Above 75% Free Cash Flow Target More than $3.5 billion by 2030 Free Cash Flow Target Status Forward-looking financial objective Therapeutic Portfolio Scope Multiple innovative medicines programmes Geographic Revenue Scope Not specified in supplied summary Strategic Time Horizon Through 2030 New Regulatory Approval No new medicine approval announced as part of the strategy update What Happened Teva presented updated R&D priorities, pipeline ambitions and financial targets for innovative medicines. Why It Matters The strategy signals Teva's intention to expand the contribution of innovative medicines to its future business and growth profile. Industry Significance Illustrates a major pharmaceutical company's emphasis on late-stage innovation, pipeline productivity and higher-value medicines. Financial Clarification The $6–7 billion revenue figure is a 2030 target rather than transaction consideration or realised revenue. Pipeline Clarification The more than $10 billion potential peak-sales estimate is not risk-adjusted or guaranteed. Key Takeaway Teva is targeting substantial innovative-medicines growth by 2030 through its late-stage pipeline and planned development programme. What to Watch Clinical readouts, regulatory submissions, launch execution, innovative-medicines revenue growth, margins and free cash flow performance. Primary Source Teva Pharmaceutical Industries Primary Source URL https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Shares-Innovative-Pipeline-Updates-and-Unveils-Path-to-Future-Growth-at-RD-Day-Targeting-67-Billion-in-Innovative-Medicines-Revenue-by-2030/default.aspx Relevant Date 11 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page